Previous 10 | Next 10 |
Third Tranche of $1.2 Million Financing Completed COLLEGE STATION, TX / ACCESSWIRE / January 19, 2021 / Enzolytics, Inc. (OTC PINK:ENZC)(the "Company") today, announced it has received the official filing receipt from the U.S. Patent Office confirming the filing of its patent applicatio...
COLLEGE STATION, TX / ACCESSWIRE / January 11, 2021 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company") today, announced it has accepted a proposal from a Houston based PCAOB Audit firm to Audit the Company's year-end financial statements, subject to the receipt and acceptance of the en...
COLLEGE STATION, TX / ACCESSWIRE / December 30, 2020 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company") today shared the following update provided by Enzolytics' CEO Charles Cotropia. The full content of the update is presented below. "December 30, 2020 To Our Shareholders, On Septe...
PLANO, TX / ACCESSWIRE / December 14, 2020 / Enzolytics, Inc. (OTC PINK:ENZC or the "Company") has engaged SAMM SOLUTIONS, INC. (DBA BTS Research), through a Master Service Agreement ("MSA"), to conduct a toxicity study on the Company's Flagship compound ITV-1. The Company has previously tes...
PLANO, TX / ACCESSWIRE / December 10, 2020 / Enzolytics, Inc. (OTC PINK:ENZC or the "Company") today announced the filing of a provisional patent with the U.S. Patent Office on December 9, 2020 for a treatment of Multiple Sclerosis developed by Harry Zhabilov, titled NUCLEAR PROTEINS ISOLAT...
PLANO, TX / ACCESSWIRE / December 1, 2020 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company") announced the execution of the definitive business combination agreement successfully merging the biotech companies Enzolytics, Inc. and BioClonetics Immunotherapeutics, Inc. on World AIDS Day....
PLANO, TX / ACCESSWIRE / November 13, 2020 / Enzolytics Inc. (OTC PINK:ENZC) or the "Company" today shared the following update provided by ENZC's Merger target BioClonetics Immunotherapeutics, Inc. ("BCLS" or "BioClonetics"), resulting from the application of proceeds from the initial fundi...
Offers Update on OTC Disclosure Filings and Initial Funding PLANO, TX / ACCESSWIRE / November 10, 2020 / Enzolytics, Inc. (OTC PINK:ENZC) or the "Company" announced the appointment of Ronald Moss, M.D., to the Medical Advisory Board of the Company. Dr. Moss has an extensive 25-year bac...
Enzolytics announces the procurement of funding for initial operations of merging entity PLANO, TX / ACCESSWIRE / October 22, 2020 / Enzolytics, Inc. (OTC PINK:ENZC) (or the "Company") announced the appointment, by the Board of Directors of the Company, on October 20 of Charles Cotropia...
Enzolytics provides guidance on engagement of manufacturer and OTC Markets Membership PLANO, TX / ACCESSWIRE / October 19, 2020 / Enzolytics, Inc. (OTC PINK:ENZC)( "ENZC" or the "Company") today shared the update provided by ENZC's Merger target BioClonetics Immunotherapeutics, Inc. ("B...
News, Short Squeeze, Breakout and More Instantly...
ALLEN, TX / ACCESSWIRE / July 26, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ( enzolytics.com ) (the "Company") stated today that the Company will whole heartedly support any and all efforts by Sagaliam Acquisition Corp ("SAGA") in its campaign to stop another attempt by NIKA Pharmaceutical and i...
BAYTOWN, TX, July 25, 2024 (GLOBE NEWSWIRE) -- Sagaliam Acquisition Corp (Expert Market: SAGA) (the “Company”) announced today that it believes that a misleading press release has been issued by Nika Pharmaceuticals, Inc. in another attempt by NIKA and its CEO, Dimtar Savov, to fa...
Update on Sagaliam Acquisition Corp. ALLEN, TX / ACCESSWIRE / July 1, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) (" enzolytics.com ") (the "Company") announced today that the Company is entering into a worldwide exclusive licensing agreement for US Patent # 8067531-B2, "Inactivated pepsin frag...